Glaukos Sets July 29 Release for Q2 2026 Results, Schedules 1:30 p.m. PT Call
Updated
Updated · BioSpace · Jul 8
Glaukos Sets July 29 Release for Q2 2026 Results, Schedules 1:30 p.m. PT Call
2 articles · Updated · BioSpace · Jul 8
Summary
July 29 is when Glaukos plans to publish its second-quarter 2026 financial results, with the release due after the market close.
1:30 p.m. PT that day, management will discuss the results on a conference call and simultaneous webcast available through the company’s investor website.
833-461-5787 for U.S. callers and 585-542-9983 for international participants will provide access to the call using conference ID 626961391.
Glaukos, an ophthalmic drug and medical technology company, is focused on glaucoma, corneal disorders and retinal diseases, including its iDose TR launch and broader dropless eye-care pipeline.